{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:06:42Z","timestamp":1785442002530,"version":"3.56.0"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,5,15]]},"DOI":"10.2169\/internalmedicine.6239-25","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:08:08Z","timestamp":1759961288000},"page":"1334-1341","source":"Crossref","is-referenced-by-count":1,"title":["Adding Semaglutide to SGLT2 Inhibitors Reduces Liver Enzymes in Patients with Type 2 Diabetes Complicated by Metabolic Dysfunction Associated Steatotic Liver Disease: A Retrospective Observational Study"],"prefix":"10.2169","volume":"65","author":[{"given":"Kanako","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Osaka International Medical &amp; Science Center (Osaka Keisatsu Hospital), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Irie","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Osaka International Medical &amp; Science Center (Osaka Keisatsu Hospital), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Osaka International Medical &amp; Science Center (Osaka Keisatsu Hospital), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Osaka International Medical &amp; Science Center (Osaka Keisatsu Hospital), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Murakawa","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Osaka International Medical &amp; Science Center (Osaka Keisatsu Hospital), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sho","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Osaka International Medical &amp; Science Center (Osaka Keisatsu Hospital), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Inui","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Osaka International Medical &amp; Science Center (Osaka Keisatsu Hospital), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Kosugi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Osaka International Medical &amp; Science Center (Osaka Keisatsu Hospital), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Hazama","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Osaka International Medical &amp; Science Center (Osaka Keisatsu Hospital), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuyuki","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Osaka International Medical &amp; Science Center (Osaka Keisatsu Hospital), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7: 851-861, 2022.","DOI":"10.1016\/S2468-1253(22)00165-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hagstr\u00f6m H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol 9: 944-956, 2024.","DOI":"10.1016\/S2468-1253(24)00193-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Stefan N, Yki-J\u00e4rvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol 13: 134-148, 2025.","DOI":"10.1016\/S2213-8587(24)00318-8"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut 72: 2138-2148, 2023.","DOI":"10.1136\/gutjnl-2023-330110"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Huang DQ, Noureddin N, Ajmera V, et al. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. Lancet Gastroenterol Hepatol 8: 829-836, 2023.","DOI":"10.1016\/S2468-1253(23)00157-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ng CH, Chan KE, Chin YH, et al. The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease. Clin Mol Hepatol 28: 565-574, 2022.","DOI":"10.3350\/cmh.2022.0096"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kim KS, Hong S, Han K, Park CY. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ 384: e076388, 2024.","DOI":"10.1136\/bmj-2023-076388"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Park J, Kim G, Kim BS, et al. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol 21: 53, 2022.","DOI":"10.1186\/s12933-022-01483-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nagahisa T, Saisho Y. Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Ther 10: 1733-1752, 2019.","DOI":"10.1007\/s13300-019-00680-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Takeshita Y, Honda M, Harada K, et al. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care 45: 2064-2075, 2022.","DOI":"10.2337\/dc21-2049"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384: 1113-1124, 2021.","DOI":"10.1056\/NEJMoa2028395"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43: 1317-1325, 2006.","DOI":"10.1002\/hep.21178"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ong Lopez AMC, Pajimna JAT. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Sci Rep 14: 2122, 2024.","DOI":"10.1038\/s41598-024-52603-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nishimiya N, Tajima K, Imajo K, et al. Effects of canagliflozin on hepatic steatosis, visceral fat and skeletal muscle among patients with type 2 diabetes and non-alcoholic fatty liver disease. Intern Med 60: 3391-3399, 2021.","DOI":"10.2169\/internalmedicine.7134-21"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Flint A, Andersen G, Hockings P, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther 54: 1150-1161, 2021.","DOI":"10.1111\/apt.16608"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 8: 511-522, 2023.","DOI":"10.1016\/S2468-1253(23)00068-7"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Volpe S, Lisco G, Fanelli M, et al. Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study. Nutrients 14: 4673, 2022.","DOI":"10.3390\/nu14214673"},{"key":"18","unstructured":"18. Govaere O, Petersen SK, Martinez-Lopez N, et al. Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. J Hepatol 76: 1001-1012, 2022."},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149: 367-378, 2015.","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of 10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci 60: 1024-1030, 2015.","DOI":"10.1007\/s10620-014-3380-3"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest 130: 1453-1460, 2020.","DOI":"10.1172\/JCI134165"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Abushamat LA, Shah PA, Eckel RH, Harrison SA, Barb D. The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis. Clin Gastroenterol Hepatol 22: 1565-1574, 2024.","DOI":"10.1016\/j.cgh.2024.01.032"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Verma S, David JP, Leiter LA, Michelsen MM, Rasmussen S, Bhatt DL. Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials. Diabetes Obes Metab 25: 2388-2392, 2023.","DOI":"10.1111\/dom.15081"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Nevola R, Epifani R, Imbriani S, et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci 24: 1703, 2023.","DOI":"10.3390\/ijms24021703"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 6: e25269, 2011.","DOI":"10.1371\/journal.pone.0025269"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice. Hepatology 43: 173-181, 2006.","DOI":"10.1002\/hep.21006"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Jane\u017e A, Fioretto P. SGLT2 inhibitors and the clinical implications of associated weight loss in type 2 diabetes: a narrative review. Diabetes Ther 12: 2249-2261, 2021.","DOI":"10.1007\/s13300-021-01104-z"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Mantsiou C, Karagiannis T, Kakotrichi P, et al. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 22: 1857-1868, 2020.","DOI":"10.1111\/dom.14108"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Liu W, You D, Lin J, et al. SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8<sup>+<\/sup> T cell activation. Cell Metab 36: 2245-2261, 2024.","DOI":"10.1016\/j.cmet.2024.08.005"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Gastaldelli A, Repetto E, Guja C, et al. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab 22: 393-403, 2020.","DOI":"10.1111\/dom.13907"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/10\/65_6239-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:26:32Z","timestamp":1778901992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/10\/65_6239-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6239-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"6239-25"}}